(Q37979497)

English

Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

scientific article published on 29 January 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

1 reference

ChEBI release 2020-05-28

systematic review

1 reference

based on heuristic

inferred from title

major depressive disorder

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

publication date

29 January 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

International Journal of Clinical Practice

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

66

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

356-368

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02885.X

21 January 2018

Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02885.X

21 January 2018

Antidepressants and Body Weight

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02885.X

21 January 2018

A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02885.X

21 January 2018

Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02885.X

21 January 2018

Distinct temporal pattern of the effects of the combined serotonin-reuptake inhibitor and 5-HT1A agonist EMD 68843 on the sleep EEG in healthy men.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02885.X

21 January 2018

Show me the evidence: using number needed to treat

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02885.X

21 January 2018

Compelling or irrelevant? Using number needed to treat can help decide

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02885.X

21 January 2018

Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02885.X

21 January 2018

Size of treatment effects and their importance to clinical research and practice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02885.X

21 January 2018

Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02885.X

21 January 2018

Is there a role for 5-HT1A agonists in the treatment of depression?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02885.X

21 January 2018

Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02885.X

21 January 2018

Patients With Severe Depression May Benefit From Buspirone Augmentation of Selective Serotonin Reuptake Inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02885.X

21 January 2018

Psychopharmacology: number needed to treat: an underused measure of treatment effect

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02885.X

21 January 2018

Solving the antidepressant efficacy question: effect sizes in major depressive disorder

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02885.X

21 January 2018

Identifiers

10.1111/J.1742-1241.2011.02885.X

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37979497&oldid=1510066914"